AJOVY Drug Profile

Summary for Tradename: AJOVY

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for AJOVY

See drug prices for AJOVY

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for AJOVY Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for AJOVY Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089		2026-11-02	DrugPatentWatch analysis and company disclosures
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089		2031-07-11	DrugPatentWatch analysis and company disclosures
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089		2035-03-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for AJOVY Derived from Patent Text Search

No patents found based on company disclosures

International Patents for AJOVY

Country	Patent Number	Estimated Expiration
Slovenia	2380592
Hong Kong	1232129
Argentina	119559
Poland	1957106
Denmark	3045182

Supplementary Protection Certificates for AJOVY

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C201930047	Spain		PRODUCT NAME: FREMANEZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1358; DATE OF AUTHORISATION: 20190328; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1358; DATE OF FIRST AUTHORISATION IN EEA: 20190328
CR 2019 00026	Denmark		PRODUCT NAME: GALCANEZUMAB; REG. NO/DATE: EU/1/18/1330 20181116
LUC00126	Luxembourg		PRODUCT NAME: FREMANEZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/19/1358 20190401
2019/040	Ireland		PRODUCT NAME: FREMANEZUMAB; REGISTRATION NO/DATE: EU/1/19/1358 20190328
C20190022 00278	Estonia		PRODUCT NAME: GALKANEZUMAB;REG NO/DATE: EU/1/18/1330 16.11.2018

Market Dynamics and Financial Trajectory for AJOVY

Last updated: February 19, 2026

Summary: AJOVY (fremanezumab-vfrm) is a monoclonal antibody approved for migraine prevention. Launched in 2018 by Teva Pharmaceutical Industries, it operates within the expanded CGRP inhibitor class. The drug’s sales are driven by a growing prevalence of chronic migraines, insurance coverage dynamics, and competition from other CGRP therapies. Market penetration remains moderate, with an increasing focus on patient groups seeking alternative dosing options. Financially, AJOVY has experienced steady revenue growth, aligned with broader trends in migraine biologics.

What Is the Market Position of AJOVY?

AJOVY is among five currently marketed CGRP inhibitors for migraine prophylaxis:

Drug Name	Launch Year	Market Share (2022)	Dosing Options	Indications
Aimovig (erenumab)	2018	45%	Monthly; quarterly	Episodic and chronic migraine
Ajovy (fremanezumab)	2018	20%	Monthly; quarterly	Episodic and chronic migraine
Emgality (galcanezumab)	2018	15%	Monthly	Episodic migraine, cluster headache
Vyepti (eptinezumab)	2020	10%	Quarterly	Migraine prevention
Ubrelvy (ubrogepant)	2019	10%	Acute mode	Acute migraine treatment

Source: IQVIA (2022).

AJOVY commands approximately 20% of the CGRP inhibitors’ market share, with sales growth offsetting competition but constrained by insurance and formulary access.

What Are the Key Drivers of AJOVY’s Market Growth?

• Increased migraine prevalence: Approximately 1 billion people worldwide suffer from migraines, with 15% suffering chronic forms—primarily adults aged 18-50 (WHO, 2021).

• Patient preference for quarterly dosing: AJOVY offers both monthly and quarterly injections, appealing to patients seeking convenience over frequent dosing regimens.

• Insurance reimbursements: Improved coverage options in the U.S. have enhanced access, with approximately 60-70% of insured patients covered following formulary inclusion.

• Clinical efficacy data: Phase III trials demonstrate a significant reduction in monthly migraine days—up to 50% in some patient groups—supporting provider adoption.

What Are the Financial Trends for AJOVY?

Revenue Overview (2020–2022):

Year	Estimated Revenue (USD millions)	Growth Rate	Notes
2020	200	—	Launch year, limited penetration
2021	350	75%	Expanded payer coverage, increasing prescribers
2022	500	43%	Market expansion, formulary wins

Sources: Teva Annual Reports (2020–2022), IQVIA sales data.

Cost Structure & Margins:

• Manufacturing costs: Approximate 10-15% of revenues, benefiting from scale efficiencies.
• Pricing: Approximate annual list price per dose is $6,000–$7,000, varying by dosing schedule.
• Margins: Gross margins around 60% align with other biologics, though net margins are compressed due to marketing and R&D expenses.

Future Revenue Projections:

• 2023–2025 CAGR: Estimated at 20–25% contingent on increased access, pipeline integration, and field force expansion.
• Market share targets: Aiming for 25–30% of CGRP class revenues by 2025, driven by more aggressive market penetration and new patient identification.

How Does AJOVY Compare to Competitors?

Drug Name	Dosing Schedule	Efficacy (Reduction in Migraine Days)	Pricing	Market Penetration
Aimovig	Monthly/quarterly	Up to 50% reduction	Similar to AJOVY	45% of CGRP market
Ajovy	Monthly/quarterly	Up to 48% reduction	Similar to Aimovig	20% of CGRP market
Emgality	Monthly	Up to 45% reduction	Slightly lower	15% of CGRP market
Vyepti	Quarterly	Up to 47% reduction	Higher (premium pricing)	10% of CGRP market

Price points converge around $6,000–$7,500 per dose, with variations based on dosing frequency, insurance contracts, and regional factors.

What Are the Key Challenges Impacting AJOVY?

• Pricing pressure: Payers push for rebates and discounts to improve access.
• Competitive pressures: New entrants and biosimilar expectations may erode market share.
• Patient adherence: While quarterly dosing helps, injectable biologics still face retention challenges.
• Regulatory hurdles: Ongoing clinical trials to expand indications require investment.

What Is the Outlook for AJOVY’s Financial Trajectory?

• Short-term (2023–2024): Revenue growth of 20–25% expected as coverage expands and prescriber awareness rises.
• Medium-term (2025–2027): Potential plateau unless new indications or combination therapies emerge.
• Long-term (beyond 2027): Growth depends on competitive landscape, biosimilar entry, and pipeline development.

Conclusion

AJOVY’s market involves steady growth driven by migraine disease prevalence, product differentiation via dosing options, and payer access enhancements. Revenue growth aligns with broader biologic trends within neurology, yet faces headwinds from pricing negotiations and competition. Ongoing clinical trials and pipeline expansion may affect future market share and financial outcomes.

Key Takeaways

• AJOVY accounts for 20–25% of the CGRP migraine prevention market.
• Revenue reached approximately $500 million in 2022, with a CAGR of over 20% projected through 2025.
• Dosing flexibility and patient preference contribute to its adoption.
• Competitive dynamics and payer pressure remain significant hurdles.
• The long-term outlook depends on pipeline success and market penetration strategies.

FAQs

1. How does AJOVY’s dosing schedule influence market share?
   Its quarterly dosing option offers increased convenience, appealing to patients and providers, compared to competitors with monthly regimens.

2. What are the primary factors affecting AJOVY’s pricing?
   Reimbursement negotiations, regional variations, and formulary placement primarily influence pricing, which hovers around $6,000–$7,000 per dose.

3. What is the expected impact of biosimilar entry on AJOVY?
   Biosimilars could reduce prices and market share, especially if they offer cost advantages, but biosimilar approval for CGRP biologics is still pending.

4. Are there upcoming indications that could boost AJOVY’s sales?
   Yes, trials are ongoing to confirm efficacy in additional migraine populations and related neurological conditions.

5. What strategic moves could enhance AJOVY’s market position?
   Expanding payer agreements, increasing prescriber outreach, and developing combination therapies could boost market share.

---

References

[1] World Health Organization. (2021). Migraine. Retrieved from https://www.who.int/news-room/fact-sheets/detail/migraine

[2] IQVIA. (2022). Market Data Reports.

[3] Teva Pharmaceutical Industries. (2020-2022). Annual Reports.